$1.14/ day, billed weekly
Cancel anytime

(Ads Free, Unlimited access)

NO CREDIT CARD REQUIRED

Skye Bioscience, Inc. Common Stock (SKYE)SKYE

Skye Bioscience, Inc. Common Stock

$5.24

Delayed price

PASS

BUY Advisory
Profitable SELL
Loss-Inducing SELL

Profit
Loss
PASS (Skip invest)*

Upturn Stock price based out of last close

Time period over

ALL
YEAR
MONTH
WEEK

Time period over

Upturn Advisory Summary

09/18/2024: SKYE (2-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Upturns

Type: Stock	Upturn Star Rating	Today’s Advisory: PASS
Profit: 52.08%	Upturn Advisory Performance 2	Avg. Invested days: 25
Profits based on simulation	Stock Returns Performance 3	Last Close 09/18/2024

Type: Stock	Today’s Advisory: PASS
Profit: 52.08%	Avg. Invested days: 25
Upturn Star Rating	Stock Returns Performance 3
Profits based on simulation Last Close 09/18/2024	Upturn Advisory Performance 2

Key Highlights

Company Size Small-Cap Stock	Market Capitalization 175.96M USD
Price to earnings Ratio -	1Y Target Price 17.6
Dividends yield (FY) -	Basic EPS (TTM) -3.6
Volume (30-day avg) 177624	Beta 1.81
52 Weeks Range 1.44 - 19.41	Updated Date 09/18/2024

Company Size Small-Cap Stock	Market Capitalization 175.96M USD	Price to earnings Ratio -	1Y Target Price 17.6
Dividends yield (FY) -	Basic EPS (TTM) -3.6	Volume (30-day avg) 177624	Beta 1.81
52 Weeks Range 1.44 - 19.41	Updated Date 09/18/2024

Earnings Date

Report Date -	When -
Estimate -	Actual -

Report Date -

When -

Estimate -

Actual -

Profitability

Profit Margin -

Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -30.92%

Return on Equity (TTM) -130.08%

Valuation

Trailing PE -	Forward PE -
Enterprise Value 91133914	Price to Sales(TTM) -
Enterprise Value to Revenue -	Enterprise Value to EBITDA -2.56
Shares Outstanding 30338300	Shares Floating 17497305
Percent Insiders 2.08	Percent Institutions 83.63

Trailing PE -	Forward PE -	Enterprise Value 91133914	Price to Sales(TTM) -
Enterprise Value to Revenue -	Enterprise Value to EBITDA -2.56	Shares Outstanding 30338300	Shares Floating 17497305
Percent Insiders 2.08	Percent Institutions 83.63

Analyst Ratings

Rating 4.4	Target Price 18.25	Buy 1
Strong Buy 3	Hold 1	Sell -
Strong Sell -

Rating 4.4	Target Price 18.25	Buy 1	Strong Buy 3
Hold 1	Sell -	Strong Sell -

About Skye Bioscience, Inc. Common Stock

Exchange	NASDAQ	Headquaters	San Diego, CA, United States
IPO Launch date	2015-04-02	Executive Chairman, President, CEO & Secretary	Mr. Punit S. Dhillon B.A.
Sector	Healthcare	Website	https://skyebioscience.com
Industry	Biotechnology	Full time employees	11
Headquaters	San Diego, CA, United States
Executive Chairman, President, CEO & Secretary	Mr. Punit S. Dhillon B.A.
Website	https://skyebioscience.com
Website	https://skyebioscience.com
Full time employees	11

Skye Bioscience, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes therapeutic drugs that modulate the endocannabinoid system. The company's lead clinical program's product candidate is nimacimab, a peripherally-restricted negative allosteric modulating antibody specific for the human cannabinoid receptor 1 (CB1) receptor, administered as a subcutaneous injectable that is Phase II clinical trials for the treatment of metabolic disorders, including obesity. It is also developing SBI-100 Ophthalmic Emulsion,a CB1 agonist that is Phase II clinical trials for the treatment of glaucoma and ocular hypertension. It has licensing agreement with Tautomer Bioscience, (Pty) Limited to develop and commercialize SBI-100; and collaborative research agreement with VivaCell Biotechnology Espana, S.L.U for the research and development of SBI-200 and the preclinical development services for novel derivatives. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

https://www.upturn.io

Disclosure Privacy Policy Terms of Use Sitemap Contact Us

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.